Efficacy and Tolerability of Lanreotide (Autogel 120 mg) in Patients With Acromegaly
Efficacy and Tolerability of Lanreotide (Autogel 120 mg) in Patients With Acromegaly
The purpose of the protocol, is to evaluate if lanreotide Autogel 120 mg is effective in the
 control of Growth Hormone (GH) secretion in patients with active acromegaly.
Inclusion Criteria:

 -  Documented diagnosis of active acromegaly, defined by serum GH levels above 5 µg/L,
 absence of reduction of serum GH levels below 1µg/L after oral glucose tolerance test
 (OGTT) and abnormal IGF-1 values

 Exclusion Criteria:

 -  Patients who have undergone pituitary surgery less than 3 months before selection

 -  Patients previously treated with radiotherapy

 -  Patients previously treated with somatostatin analogue except for a pre-surgical
 treatment not longer than 3 months